Awwal Gambo
8 Papers
7 Citations
Awwal Gambo is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Stroke. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Sickle Cell Disease Genomics of Africa (SickleGenAfrica) Network: ethical framework and initial qualitative findings from community engagement in Ghana, Nigeria and Tanzania.
Kofi A. Anie,Kofi A. Anie,Edeghonghon Olayemi,Vivian Paintsil,Vivian Paintsil,Ellis Owusu-Dabo,Titilope A Adeyemo,Mahmoud U Sani,Najibah A. Galadanci,Obiageli E Nnodu,Furahini Tluway,David N. Adjei,Peter Mensah,Joseph Sarfo-Antwi,Henry Nwokobia,Awwal Gambo,Adebola Benjamin,Arafa Salim,Judith A Osae-Larbi,Solomon F. Ofori-Acquah +19 more
TL;DR: In this paper, the Sickle Cell Disease Genomics of Africa Network (SCDNGAN) is proposed to provide lay information about genetics and sickle cell disease (SCD) and to identify and address ethical issues concerning the NCGAN.
16
Randomized controlled trial of fixed low-vs moderate-dose hydroxyurea for primary stroke prevention in Sub-Saharan Africa: Final results of the Spring Trial
Shehu U. Abdullahi,Binta W. Jibir,Halima Bello-Manga,Safiya Gambo,Hauwa Inuwa,Aliyu Tijjani,Aisha Amal Galadanci,Awwal Musa Borodo,Najibah A. Galadanci,Nura Idris,Abulkadir M Tabari,Lawal Haliru,Khadija Bulama,Gloria Bahago,Mohammed A. Sani,Aisha A. Suleiman,Murtala Umar,Charity Dooshima,Aisha Kazaure,Bilya Sani Musa,Fahad M Usman,Abdulrasheed Sani,Awwal Gambo,Jamila Sani Ibrahim,Mustapha Shuaibu Hikima,Aisha B. Musa,Abdu Hamisu Dambatta,Jamil Galadanci,Brittany Covert Greene,Djamila L. Ghafuri,Mark Rodeghier,James C. Slaughter,Fenella J. Kirkham,Kathleen A. Neville,Adetola A. Kassim,Muktar H. Aliyu,Lori C. Jordan,Edwin Trevathan,Michael R. DeBaun +38 more
TL;DR: Testing the hypothesis that fixed-moderate dose hydroxyurea therapy for primary stroke prevention results in a 66% relative risk reduction when compared to fixed low-dose hydroxyUREa therapy in a randomized controlled trial, found it to be effective.
7
Barriers and Facilitators of Premarital Genetic Counseling for Sickle Cell Disease in Northern Nigeria
Aisha Amal Galadanci,Jeremie H. Estepp,Hamda Khan,Zubaida L Farouk,Yvonne Caroll,Jason R. Hodges,Sabiu Yarima,Umma A. Ibrahim,Ibrahim Musa Idris,Awwal Gambo,Nafiu Hussaini,Aisha Mukaddas,Michael Dean,Najibah A. Galadanci +13 more
TL;DR: A willingness to receive premarital testing for SCD exists within the community to reduce the spread of the disease and advocate for improved health-related quality of life of patients with SCD and parents of the patients with or without SCD.
4
Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
Shehu U. Abdullahi,Binta J. Wudil,Halima Bello-Manga,Aisha B. Musa,Safiya Gambo,Najibah A. Galadanci,Hauwa Aminu,Aliyu Tijjani Gaya,Surayya Sanusi,Musa A. Tabari,Aisha Amal Galadanci,Awwal Musa Borodo,Muhammed S. Abba,Abdu Hamisu Dambatta,Lawal Haliru,Awwal Gambo,Holly Cassell,Mark Rodeghier,Djamila L. Ghafuri,Brittany Covert Greene,Kathleen Neville,Adetola A. Kassim,Adetola A. Kassim,Fenella J. Kirkham,Edwin Trevathan,Lori C. Jordan,Muktar H. Aliyu,Michael R. DeBaun +27 more
TL;DR: The primary hypothesis is that there will be a 66% relative risk reduction of strokes in children with SCA and abnormal TCD measurements, randomly allocated, for a minimum of three years to receive moderate fixed-dose versus low fixed- dose hydroxyurea therapy.
Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa
Djamila L. Ghafuri,Brittany Covert Greene,Bilya Sani Musa,Awwal Gambo,Abdulrasheed Sani,Shehu U. Abdullahi,Binta J. Wudil,Halima Bello-Manga,Safiya Gambo,Matin Ghafuri,Holly Cassell,Kathleen A. Neville,Fenella J Kirkham,Adetola A. Kassim,Muktar H. Aliyu,Michael R. DeBaun,Lori C. Jordan +16 more
TL;DR: In this article, the authors describe capacity-building strategies in conjunction with two National Institutes of Health-funded primary stroke prevention trials (a feasibility trial and phase III randomized controlled trial) with initial hydroxyurea treatment for children with SCA and abnormal transcranial Doppler (TCD) velocities in Nigeria.